Clinical Trial Update: Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting completed Phase 1/2 evaluation of combining siltuximab and spartalizumab in metastatic pancreatic cancer; results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Spartalizumab (spartalizumab)
• Sylvant (siltuximab)

Snippet

Sponsor: Emory University | Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-08-22